Very Low Prostate PET/CT PSMA Uptake May Be Misleading in Staging Radical Prostatectomy Candidates.

imaging prostate cancer prostate-specific membrane antigen (PSMA) radical prostatectomy staging

Journal

Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269

Informations de publication

Date de publication:
06 Mar 2022
Historique:
received: 01 01 2022
revised: 26 02 2022
accepted: 02 03 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 26 3 2022
Statut: epublish

Résumé

Purpose: to evaluate a unique subpopulation of radical prostatectomy (RP) candidates with “negative” prostate 68Ga-labeled prostate-specific membrane antigen (PSMA) positron emission tomography (PET) computed tomography (CT) imaging scans and to characterize the clinical implications of misleading findings. Materials and Methods: This case-control retrospective study compared the final histological outcomes of patients with “negative” pre-RP PSMA PET/CT prostate scans (with a prostate maximal standardized uptake value [SUVmax] below the physiologic uptake) to those with an “intense” prostatic tracer uptake (with a SUVmax above the physiologic uptake). The patients underwent an RP between March 2015 and July 2019 in five academic centers. Data on the demographics, comorbidities, prostate-specific antigen (PSA) and rectal exam findings, prior biopsies, imaging results, biopsies, and RP histology results were collected. Results: Ninety-seven of the 392 patients who underwent an RP had PSMA PET/CT imaging preoperatively. Fifty-two (54%) had a “negative” uptake (in the study group), and 45 (46%) had a “positive” uptake (in the control group). Only the lesion size and SUVmax values on the PSMA PET/CT differed between the groups preoperatively. On the histological analysis, only the ISUP score, seminal vesicles invasion, T stage, and positive margin rates differed between the groups (p < 0.05), while 50 (96%) study group patients harbored clinically significant disease (ISUP ≥ 2), with an extra-prostatic disease in 24 (46%), perineural invasion in 35 (67%), and positive lymph nodes in 4 (8%). Conclusions: Disease aggressiveness generally correlated with an intense PSMA uptake on the preoperative PSMA PET/CT, but a subpopulation of patients with clinically significant cancer and aggressive characteristics showed a deceptively weak PSMA uptake. These data raise a concern about the unqualified application of PSMA PET/CT for staging RP candidates.

Identifiants

pubmed: 35330410
pii: jpm12030410
doi: 10.3390/jpm12030410
pmc: PMC8951096
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Mol Metab. 2018 Feb;8:158-166
pubmed: 29249638
J Nucl Med. 2018 Feb;59(2):238-243
pubmed: 28775203
Eur J Nucl Med Mol Imaging. 2018 Feb;45(2):235-242
pubmed: 29075832
Cancer Imaging. 2015 Mar 03;15:2
pubmed: 25889163
J Nucl Med. 2019 Mar;60(3):362-368
pubmed: 30042163
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541
Eur J Nucl Med Mol Imaging. 2021 Nov;48(12):4042-4053
pubmed: 34386839
EJNMMI Res. 2019 Feb 8;9(1):15
pubmed: 30737563
Clin Cancer Res. 2018 Dec 15;24(24):6300-6307
pubmed: 30139879
Eur J Radiol. 2021 Mar;136:109556
pubmed: 33485127
Endocr Relat Cancer. 2018 Oct 1;26(2):131-146
pubmed: 30400059
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
J Nucl Med. 2016 Nov;57(11):1720-1725
pubmed: 27261520
Insights Imaging. 2011 Dec;2(6):679-698
pubmed: 22347986
Radiographics. 2018 Jan-Feb;38(1):200-217
pubmed: 29320333
Medicine (Baltimore). 2014 Nov;93(26):e254
pubmed: 25474437
Prostate Cancer Prostatic Dis. 2021 Jun;24(2):423-430
pubmed: 32999466
Eur Urol. 2016 Oct;70(4):553-557
pubmed: 26810345
Eur Urol. 2018 May;73(5):656-661
pubmed: 29358059
Curr Radiopharm. 2018;11(1):4-13
pubmed: 29090673
Abdom Radiol (NY). 2020 Dec;45(12):4194-4201
pubmed: 32671440
Eur Urol. 2019 Oct;76(4):469-478
pubmed: 31345636
Nat Rev Urol. 2021 Feb;18(2):79-92
pubmed: 33328650
World J Urol. 2018 Apr;36(4):519-527
pubmed: 29344682
EJNMMI Res. 2020 Nov 10;10(1):138
pubmed: 33169183
Eur Urol. 2016 Dec;70(6):926-937
pubmed: 27363387
BJU Int. 2017 Feb;119(2):209-215
pubmed: 27207581
AJR Am J Roentgenol. 2004 May;182(5):1129-32
pubmed: 15100107
EJNMMI Res. 2022 Feb 11;12(1):10
pubmed: 35147810
Nucl Med Commun. 2019 Jan;40(1):86-91
pubmed: 30395048
J Nucl Med. 2010 Jul;51(7):1015-20
pubmed: 20554733
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):941-949
pubmed: 28138747

Auteurs

Barak Rosenzweig (B)

Department of Urology, Chaim Sheba Medical Center, Ramat Gan 5211401, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.

Rennen Haramaty (R)

Department of Urology, Chaim Sheba Medical Center, Ramat Gan 5211401, Israel.

Tima Davidson (T)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Department of Nuclear Medicine, Chaim Sheba Medical Center, Ramat Gan 5211401, Israel.

Alon Lazarovich (A)

Department of Urology, Chaim Sheba Medical Center, Ramat Gan 5211401, Israel.

Asaf Shvero (A)

Department of Urology, Chaim Sheba Medical Center, Ramat Gan 5211401, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.

Miki Haifler (M)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Department of Urology, Shamir Medical Center, Tzrifin 6093000, Israel.

Jonathan Gal (J)

Department of Urology, Shamir Medical Center, Tzrifin 6093000, Israel.

Shay Golan (S)

Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
Section of Urology, Rabin Medical Center, Petah Tikva 4941492, Israel.

Sagi Shpitzer (S)

Section of Urology, Rabin Medical Center, Petah Tikva 4941492, Israel.

Azik Hoffman (A)

Department of Urology, Rambam Health Center, Haifa 3109601, Israel.
Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa 3200003, Israel.

Omri Nativ (O)

Department of Urology, Rambam Health Center, Haifa 3109601, Israel.

Yuval Freifeld (Y)

Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa 3200003, Israel.
Department of Urology, Carmel Medical Center, Haifa 3436212, Israel.

Rani Zreik (R)

Ruth and Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa 3200003, Israel.

Zohar A Dotan (ZA)

Department of Urology, Chaim Sheba Medical Center, Ramat Gan 5211401, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.

Classifications MeSH